SCHEMBL3195875

SCHEMBL3195875

O=C(O)CCNC(=O)c1ccccc1O

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 3/20 0.64
▸ HSD17B10 Q99714 3/20 0.64
▸ NPSR1 Q6W5P4 2/20 0.64
▸ HTT P42858 2/20 0.64
▸ ALDH1A1 P00352 2/20 0.64
▸ NPC1 O15118 1/20 0.64
▸ MAPT P10636 1/20 0.64
▸ TSHR P16473 1/20 0.64
▸ NLRP1 Q9C000 1/20 0.64
▸ NAAA Q02083 1/20 0.59
▸ KDM4E B2RXH2 2/20 0.53
▸ MPO P05164 1/20 0.53
▸ GAA P10253 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ HIF1A Q16665 1/20 0.53
▸ MEN1 O00255 3/20 0.53
▸ KMT2A Q03164 3/20 0.53
▸ LMNA P02545 1/20 0.53
▸ TP53 P04637 1/20 0.53
▸ ALOX5 P09917 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1707464 0.90 NPC1 (0.69) HPGDHSD17B10NPSR1HTTALDH1A1
SCHEMBL4955777 0.89 PPARG (0.61) HPGDHSD17B10NPSR1HTTALDH1A1
SCHEMBL5655254 0.88 ALDH1A1 (0.68) HPGDHSD17B10NPSR1HTTALDH1A1
SCHEMBL664024 0.87 NAAA (0.70) HPGDHSD17B10NPSR1HTTALDH1A1
SCHEMBL6383063 0.87 NAAA (0.70) HPGDHSD17B10NPSR1HTTALDH1A1
SCHEMBL14088979 0.87 NAAA (0.70) HPGDHSD17B10NPSR1HTTALDH1A1
SCHEMBL14088978 0.87 NAAA (0.70) HPGDHSD17B10NPSR1HTTALDH1A1
SCHEMBL2331916 0.87 NAAA (0.70) HPGDHSD17B10NPSR1HTTALDH1A1
SCHEMBL13593340 0.87 NAAA (0.70) HPGDHSD17B10NPSR1HTTALDH1A1
Salcaprozic Acid SCHEMBL4586235 0.87 NAAA (0.70) HPGDHSD17B10NPSR1HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8937090-B2 Parakeratosis inhibitor, pore-shrinking agent and external composition for skin SHISEIDO COMPANY, LTD. (JP) 2015-01-20 — — US disclosed
US-8785381-B2 Oral GLP-1 formulations EMISPHERE TECHNOLOGIES, INC. (US) 2014-07-22 — — US disclosed
US-8785381-B2 Oral GLP-1 formulations EMISPHERE TECHNOLOGIES, INC. (US) 2014-07-22 — — US disclosed
US-20120232111-A1 Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin SHISEIDO COMPANY, LTD. (JP) 2012-09-13 — — US disclosed
US-20100035881-A1 WRINKLE-IMPROVING AGENT SHISEIDO COMPANY, LTD. (JP) 2010-02-11 — — US disclosed
US-20100016229-A1 Oral GLP-1 Formulations NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) 2010-01-21 — — US disclosed
US-20100016229-A1 Oral GLP-1 Formulations NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) 2010-01-21 — — US disclosed
EP-1941861-A1 WRINKLE-IMPROVING AGENT Shiseido Company, Limited (JP) 2008-07-09 — — EP disclosed
EP-1880711-A1 PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN Shiseido Company, Limited (JP) 2008-01-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035881-A1 WRINKLE-IMPROVING AGENT AAAS, GLA, COL14A1 HPGD 1474/4885HSD17B10 1123/4885NPSR1 2216/4885
US-20120232111-A1 Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin CUTA, AAAS, NUP160 HPGD 2394/4885HSD17B10 2725/4885NPSR1 4560/4885
US-20100016229-A1 Oral GLP-1 Formulations GLP1R, GIPR, GCGR HPGD 1795/4885HSD17B10 1943/4885NPSR1 415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback